Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

Iacono, Salvatore; Stefano, Vincenzo Di; Alonge, Paolo; Vinciguerra, Claudia; Milella, Giammarco; Caputo, Francesca; Lasorella, Piergiorgio; Neto, Gabriele; Pignolo, Antonia; Torrente, Angelo; Lupica, Antonino; Ajdinaj, Paola; Firenze, Alberto; Tozza, Stefano; Manganelli, Fiore; Muzio, Antonio Di; Piscosquito, Giuseppe; Brighina, Filippo

doi:10.3390/brainsci12101396

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also important to note that women under 30 years of age had the most side effects after vaccination in the form of local pain, headache, myalgias, etc. [37]. In our work, one woman developed GBS after vaccination.…”

Section: Discussionmentioning

confidence: 48%

Analysis of Post-COVID-19 Guillain–Barré Syndrome over a Period of One Year in the University Hospital of Split (Croatia)

Dunkić,

Nazlić,

Dunkić

et al. 2023

Neurology International

View full text Add to dashboard Cite

The virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is capable of attacking the nervous system in several ways and leading to neurological diseases such as GBS (Guillain–Barré syndrome) through the resulting neurotropism and immune response. The aim of this study is to show the relationship between Coronavirus disease (COVID-19) and GBS and to better understand the clinical symptoms to prevent poor outcomes. Data from 15 patients were extracted from the Department of Neurology, University Hospital of Split, Croatia, for the year 2021. The age of the patients ranged from 26 to 89 years, of whom 27% were women. Sixty seven percent of all GBS patients recovered from COVID-19 infection, whereas post-vaccinal polyradiculoneuritis was detected in 6%. Forty four percent of the patients who developed GBS had a severe form of COVID-19 infection. Forty percent of patients were treated with intravenous immunoglobulins (IVIG), followed by therapeutic plasma exchange (PLEX) in 27%. After the therapy, improvement was observed in 13 patients, while two patients died. The results suggest that SARS-CoV-2 triggers GBS because it follows a similar pattern of infection as the other viral and bacterial agents that contribute to the onset of GBS. There is no evidence that prior infection with COVID-19 worsens the clinical presentation of GBS.

show abstract

Section: Discussionmentioning

confidence: 48%

Analysis of Post-COVID-19 Guillain–Barré Syndrome over a Period of One Year in the University Hospital of Split (Croatia)

Dunkić,

Nazlić,

Dunkić

et al. 2023

Neurology International

View full text Add to dashboard Cite

show abstract

“…The spectrum of reported neurological sequelae associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination or COVID-19 infection is continuously expanding, facial nerve palsy (1), Guillain Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenic disorders being among them (2)(3)(4), but the impact of vaccination and COVID-19 infection on genetic disorders such as Charcot-Marie Tooth (CMT) are unclear at present.…”

Section: Introductionmentioning

confidence: 99%

Case report: Chronic inflammatory demyelinating polyneuropathy superimposed on Charcot–Marie-tooth type 1A disease after SARS-CoV-2 vaccination and COVID-19 infection

Li,

Yu,

Zhou

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundThere is growing evidence that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or COVID-19 infection is associated with the development of immune mediated neuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP), but the impact of SARS-CoV-2 vaccination and COVID-19 infection on genetic disorders such as Charcot–MarieTooth (CMT) remains unclear.Case presentationA 42-year-old male with occulted CMT neuropathy type lA (CMT1A) who developed limb numbness and weakness after the second SARS-CoV-2-vaccination was confirmed by identifying characteristic repeats in the p11.2 region of chromosome 17. Due to the progressive deterioration of muscle strength over 8 weeks, limb atrophy, moderately elevated protein counts in the cerebrospinal fluid, and significant improvement with intravenous human immunoglobulin, which were characteristic of acquired inflammatory neuropathies, he was eventually diagnosed with CIDP superimposed on CMT1A. However, after a three-month plateau, the patient contracted COVID-19, which led to repeated and worsening symptoms of limb weakness and atrophy, thus was diagnosed with a recurrence of CIDP and treated with Intravenous immunoglobulin and methylprednisolone 500 mg/d for 5 consecutive days, followed by oral prednisone and mycophenolate mofetil tablets. On 2 month follow-up, he exhibited remarkable clinical improvement and could walk independently with rocking gait. After 1 year of follow-up, the patient’s condition was stable without further change.ConclusionOur case indicates that CMT1A can deteriorate after SARS-CoV-2 vaccination. Thus, SARS-CoV-2 vaccination should be considered a potential predisposing factor for CMT1A worsening. The possible superposition of CMTIA and CIDP in the context of SARS-CoV-2 infection or immunity suggests that any clinical exacerbation in patients with CMT1A should be carefully evaluated to rule out treatable superposition inflammation. In addition, electrophysiological and imaging examination of the proximal nerves, such as the axillary nerve, is helpful for the diagnosis of CIDP.

show abstract

“…The onset of respiratory symptoms was subtle in our patients, and a slow worsening occurred, so they did not undergo a nasopharyngeal swab to check for possible SARS-CoV-2 infection. Considering the evidence supporting vaccination in patients with polyneuropathy ( 36 ), both patients received multiple doses of the anti-SARS-CoV-2 mRNA-based vaccine. They reported no SARS-CoV-2 infection, yet the potential role of an unrecognized infection at the onset of respiratory symptoms cannot be ruled out.…”

Section: Review Of the Literature And Discussionmentioning

confidence: 99%

Respiratory involvement and sleep-related disorders in CMT1A: case report and review of the literature

Massucco,

Schenone,

Faedo

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

Sleep-disordered breathing has been reported in Charcot–Marie–Tooth disease (CMT) type 1A in association with diaphragmatic weakness and sleep apnea syndrome, mainly of the obstructive type (OSA). Improvement has been observed not only in sleep quality but also in neuropathy symptoms in CMT1A patients with OSA following the initiation of continuous positive airway pressure. We report the cases of two siblings affected by CMT1A associated with hemidiaphragm relaxatio necessitating nocturnal non-invasive ventilation (NIV). Two twins, now 42 years old, with a family history of CMT1A, received a genetic diagnosis of CMT1A at the age of 16. Over the years, they developed a slowly worsening gait disorder and a decline in fine motor hand movements, currently presenting with moderate disability (CMTES:13). At the age of 40, they both started complaining of daytime sleepiness, orthopnea, and exertional dyspnea. They received a diagnosis of relaxatio of the right hemidiaphragm associated with impairment of nocturnal ventilation and they both have benefited from nocturnal NIV. Disorders of breathing during sleep may be underestimated in CMT1A since routine investigations of sleep quality are rarely performed. Our two clinical cases and a literature review suggest the importance of inquiring about symptoms of excessive daytime sleepiness and respiratory disturbances in individuals with CMT1A, even in the absence of severe neuropathy. In the presence of compatible symptoms, a pneumological assessment, along with an overnight polysomnogram and lung function tests, should be performed. Recognizing sleep-related symptoms is essential for providing accurate treatment and improving the quality of life for patients with CMT1A.

show abstract

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

Cited by 3 publications

References 30 publications

Analysis of Post-COVID-19 Guillain–Barré Syndrome over a Period of One Year in the University Hospital of Split (Croatia)

Analysis of Post-COVID-19 Guillain–Barré Syndrome over a Period of One Year in the University Hospital of Split (Croatia)

Case report: Chronic inflammatory demyelinating polyneuropathy superimposed on Charcot–Marie-tooth type 1A disease after SARS-CoV-2 vaccination and COVID-19 infection

Respiratory involvement and sleep-related disorders in CMT1A: case report and review of the literature

Contact Info

Product

Resources

About